Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1241 in Combination with Efruxifermin Shows Enhanced ...

Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” ...

Title: Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY) ...

Efruxifermin also appeared to be associated with improvements in MASH-related histologic findings, noninvasive markers of liver injury and fibrosis, and markers of glucose and lipid metabolism.

Efruxifermin had previously failed a phase 2 study, but Akero's management had argued that treating patients for longer might result in a different outcome. Turns out they were right.

Key Takeaways. Efruxifermin (EFX) with GLP-1RA significantly reduces hepatic fat fraction and improves fibrosis in MASH and T2D patients. The study involved 31 patients over 12 weeks, showing EFX ...

Efruxifermin (EFX), Akero's lead product candidate for MASH, is currently being evaluated in three ongoing Phase 3 studies. In multiple Phase 2 studies, EFX has been observed to reverse fibrosis ...

-- 601 patients have been enrolled in the double-blind portion of the SYNCHRONY Real-World study since initiation in November 2023 -- -- Data from SYNCHRONY Real-World study anticipated in the ...

On Monday, Citi initiated coverage on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) stock with a positive outlook, assigning the stock a Buy rating and setting a price target of $65.00. Akero Therapeutics, ...

The analyst from Citi also highlighted efruxifermin's potential to stand out in the treatment of cirrhotic MASH due to its anti-fibrotic benefits.

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...